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Defective expression of B7-2 (CD86) on monocytes of dialysis clinical problems arise from viral infections like viral hep-
patients correlates to the uremia-associated immune defect. atitis or influenza. Vaccinations in patients with CRF lead
Background. Specific cellular immune reactions in patients mostly to impaired results with low antibody titers and awith chronic renal failure (CRF) are impaired by a defect of
short duration of protection, and nonresponsiveness tothe antigen-presenting cells. To elucidate the molecular back-
standard vaccination protocols is common [2–4].ground for this defect, we determined the expression of human
lymphocyte antigen (HLA)-DR and costimulatory molecules These complications arise from a secondary immune
on monocytes of hemodialysis patients. defect that is very common in patients with CRF [5]. The
Methods. The expression of HLA-DR, B7-1 (CD80), and
response to a standardized quadruple vaccination againstB7-2 (CD86) molecules was determined on CD141 monocytes
hepatitis B has been established as a valuable means toof chronic hemodialysis patients prior to a dialysis session.
Mononuclear cells of these patients were cultured, and expres- estimate the individual cellular immune function in renal
sion of the respective antigens was determined after in vitro failure [6]. Nonresponse to hepatitis B vaccine is accom-
activation by various stimuli. Results were correlated with in panied by an impaired activation of T lymphocytes invitro proliferation of T cells in a phytohemagglutinin (PHA)
vitro and a reduced secretion of the T-cell growth factorassay and the clinical response to a hepatitis B vaccination.
interleukin-2 (IL-2) in conjunction with enhanced ex-All data were compared with healthy controls and patients
with CRF who were not on dialysis. pression of IL-2 receptors [7]. Nevertheless, T-cell activa-
Results. Monocytes of chronic hemodialysis patients but not tion in CRF patients is normal in the presence of acces-
CRF patients expressed low levels of costimulatory B7-2, while
sory cells from healthy donors [6, 8]. Thus, the defectHLA-DR expression was normal. B7-1 was only expressed on
could be localized to the accessory or antigen presentingactivated monocytes, and the expression reached normal levels
in hemodialysis patients. Baseline expression of B7-2 highly cell (APC) instead of the T cell itself. Indirect evidence
correlated with the results of T-cell proliferation assays in he- showed that the costimulatory system of B7 molecules
modialysis patients and also with the clinical immune response. on APCs is most relevant for the defect, since supple-
Conclusions. Impaired expression and up-regulation of B7-2
mentation of B7 signals in vitro led to a normalizationis an important feature of the cellular immune defect in chronic
of T-cell function [6].hemodialysis patients. It leads to reduced costimulation and
effector activation of T cells and contributes to a molecular In addition to the first activation signal of APCs toward
explanation for the impaired response of hemodialysis patients the CD41 T cell, which is transmitted via antigen-specific
to the hepatitis B vaccination. peptides in the binding groove of the major histocompat-
ibility complex (MHC) class II molecule, secondary sig-
nals are required for T-cell activation [9]. A crucial signal
Infection accounts for much of the morbidity, hospital- that determines whether a T cell becomes activated or
ization, and death of patients with chronic renal failure inactivated is derived from molecules of the B7 family:
(CRF). The 1998 U.S. Renal Data System report showed B7-1 (CD80) and B7-2 (CD86) with different expression
infection to be the second most frequent single cause of characteristics and binding profiles to their ligands CD28
death (15.5%) following cardiovascular events [1]. Many and CTLA-4 on T cells [10]. Binding of B7 molecules
to CD28 on T cells strongly enhances the production of
IL-2 [11]. It thus seems reasonable that a putative defectKey words: antigen presenting cells, immunity, kidney failure, mono-
cytes, T-lymphocytes, cellular immune defect, chronic renal failure. in B7 signaling leads to a phenotype similar to the one
observed in CRF.
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Table 1. Characteristics of the patients according to their immune interstitial nephritis (N 5 2), analgesic nephropathy (N 5
response to a hepatitis B vaccination 1), nephrocalcinosis (N 5 1), and renal tuberculosis (N 5
Responder Nonresponder 1), and the renal disease was unknown in four patients.
CRF patients had an average creatinine clearance ofAge years 61.0610.7 66.6611.2
Synthetic membrane 5/12 2/8 9.4 6 3.3 mL/min. In this patient group, renal failure
HD time per session min 208.3640.0 198.5637.1 was due to diabetic nephropathy (N 5 3), chronic glo-Kt/Vdp 0.9360.32 0.9260.3
merulonephritis (N 5 1), cystic disease (N 5 1), andBMI kg/m2 25.965.6 24.466.5
Diabetics 4/12 1/8 nephrosclerosis (N 5 3), and the renal disease was un-
Hematocrit % 33.865.3 29.964.6 known in two patients. Healthy control persons cameParathormone pmol/L 106.3690.3 145.56143.6
from our clinic and laboratory personnel and had a meanCRP mg/L 7.067.6 15.1617.4
Erythropoietin dose IU/week 541764981 412563563 age of 30.1 6 3.9 years. During the evaluation of these
Calcitriol treatment 6/12 4/8 methods, we compared a group of healthy persons aged
Comparison of responders and nonresponders was done by Mann-Whitney 60.7 6 4.5 years with a group aged 29.7 6 3.2 years (N 5
test or Chi-square test as applicable. There were no statistically significant differ-
10 each) and found no differences with respect to theences between both patient groups. Abbreviations are: HD, hemodialysis; Kt/Vdp,
dialysis dose, double-pool urea kinetics [12]; BMI, body mass index; CRP, expression of B7 molecules (data not shown).
C-reactive protein.
Classification of the clinical immune status
Hemodialysis patients were classified as responders or
nonresponders to the hepatitis B vaccination accordingconstitutive and regulated expression of B7 molecules
to the results of a standard vaccination protocol withon monocytes of chronic hemodialysis patients.
HBsAg. Antibody titers were determined after four in-
jections of 40 mg hepatitis B vaccine (Engerix B, SKB,
METHODS Go¨ttingen, Germany) at zero, one, six, and nine months.
Responders had $10 IU/mL anti-HBs four weeks afterPatients
the fourth vaccination, and nonresponders had ,10Twenty chronic hemodialysis patients from our outpa-
IU/mL.tient dialysis clinic and 10 patients with CRF not on renal
replacement therapy who gave informed consent were Blood sampling and cell preparation
included in this study. Exclusion criteria were clinical
Blood samples were drawn from the arterial line be-signs for the presence of an acute inflammatory process,
fore the start of a hemodialysis treatment or by venipunc-the use of immunosuppressive drugs, or evidence of ma-
ture in CRF patients and healthy controls in the morning.lignancy. Patients were checked for bronchiopulmonal
Blood was collected into heparinized syringes (1000 Uinfections and skin lesions, particularly gangrene, by clin-
sodium heparin per 20 mL blood). All specimens wereical examination. Patients were excluded if leukocytes
placed on ice immediately, and further processing took
exceeded 10,000 per mL or if the CRP was more than place at 48C. Peripheral blood mononuclear cells (PBMCs)
10% above values of the last six months. The mean age were prepared by density gradient centrifugation (Ficoll
of the hemodialysis patients was 63.3 6 11.0 years, and 1.077; Linaris, Bettingen, Germany), washed twice in
that of CRF patients was 71.1 6 10.3 years. Average phosphate-buffered saline (PBS), and then either stained
dialysis time was 204 6 38 min three times weekly, and immediately for the determination of constitutive ex-
the Kt/V was 0.92 6 0.30 per dialysis session (calculated pression of surface molecules or cultured for 20 hours
according to Daugirdas and Ing; double-pool urea kinet- in RPMI 1640 (VLE-RPMI, very low endotoxin content;
ics) [12]. Thirteen patients were treated with hemophan Biochrom, Berlin, Germany) supplemented with 5% fe-
dialyzers (GFS plus 20; Gambro, Hechingen, Germany), tal calf serum (FCS; Biochrom), 2 mmol/L glutamine, and
and seven patients were treated with synthetic mem- antibiotics. Cell culture for surface staining took place at
branes (polysulfone, F60, F8; Fresenius, Bad Homburg, 2 3 106 cells/mL in plastic dishes coated with poly(2-
Germany; polyamide, Polyflux 17; Gambro). Dialyzers hydroxyethyl-methacrylate) (PHEMA; Sigma Chemi-
were not reused. Bicarbonate dialysate was supplied via cals, Deisenhofen, Germany) to prevent adherence of
a central supply system. Dialysate quality was tested monocytes to the plastic surface. These dishes enabled us
weekly and met the Association for the Advancement to culture monocytes for up to 48 hours without cellular
of Medical Instrumentation (AAMI) criteria. Twelve pa- activation. Stimulation of cells was done by either inter-
tients were responders to the hepatitis B vaccination feron-g (IFN-g) at 200 U/mL (PBH, Hannover, Ger-
(discussed later in this article), and eight were nonre- many) or db-cAMP (Sigma Chemicals) at 300 mg/mL.
sponders. Further characteristics of the patients are given
Staining and flow cytometryin Table 1. Renal failure occurred because of the follow-
ing diseases: diabetic nephropathy (N 5 5), chronic glo- Cell surface antigens were detected by labeling PBMCs
with the following murine monoclonal antibodies specificmerulonephritis (N 5 4), cystic disease (N 5 2), chronic
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for the molecules: B7-1, FHM1; B7-2, IT2.2 (Phar-
mingen, Hamburg, Germany); CD14, IOT14 PE-labeled
(Dianova, Hamburg, Germany); HLA class II, IOT 2a
FITC-labeled (Dianova). FHM1 is a mouse monoclonal
antibody raised against a human B7-1IgGFc fusion pro-
tein. It shows the same staining characteristics as the
B7-24 antibody [13] on a number of cell lines and on
mouse fibroblasts transfected with human B7-1 (kindly
provided by M. De Boer, Ghent, Belgium). FHM1 and
B7-24 competitively inhibit each other’s binding.
For staining of B7, 5 3 105 cells were incubated with
primary antibodies at a saturating concentration for 20
minutes at 48C. Subsequently, cells were washed twice
in cold PBS and stained with FITC-labeled goat anti-
mouse F(ab)2 fragments (Dianova). Negative controls
did not receive any primary antibody. Finally, cells were
stained with the directly labeled CD14-PE. HLA-DR
molecules were simultaneously stained with CD14 using
IOT2a-FITC. Samples were analyzed with a FACScan
flowcytometer and the LYSYS II software (Becton Dick-
inson, Heidelberg, Germany). Generally, a forward and
side scatter gate was set for the analysis of monocytes
into which 5 3 103 cells per sample were counted. For
the measurements of B7 or HLA class II molecules, a
gate was set on fluorescence 2 to detect CD14-positive
cells exclusively. Further analysis of the list mode data
was done on a personal computer with the WinMDI 2.7
system provided by J. Trotter (Scripps Research Insti-
tute, La Jolla, CA, USA). The percentage of cells posi-
tive for a surface antigen was calculated against a nega-
tive control with the specific primary antibody omitted
during the staining procedure. Cut-off markers were set
individually for each measurement according to the neg-
ative control. Fluorescence intensity for a surface antigen
was calculated as geometric mean (MFI) of all cells
above cutoff.
Proliferation assays
Peripheral blood mononuclear cells were cultured at
1 3 105 per well (200 mL) in 96-well round-bottom micro-
titer plates (Greiner, Nu¨rtingen, Germany) in supple-
mented RPMI 1640 with 250 ng/mL PHA-L (Biochrom).
The assays were done in quadruplicate. After 24 hours
Fig. 1. Expression of surface antigens on monocytes of healthy controls
of incubation, the tests were pulsed with 0.25 mCi/well and hemodialysis patients stratified according to their response to a
hepatitis B vaccination. Surface antigens were detected by flow cytome-3H-thymidine (ICN, Eschwege, Germany), further in-
try on freshly isolated PBMCs after gating for CD141 cells. (A) Thecubated overnight, harvested on glassfiber mats, and
expression density of B7-2. (B) Expression of HLA-DR. (C) Expression
counted in a liquid scintillation counter (Microbeta 1450; density of CD14. Data are given as mean fluorescence intensity (MFI)
values. Bars indicate the geometric mean of each column. *P , 0.05;Wallac, Freiburg, Germany).
**P , 0.01.
Statistics
Data management and statistical analysis were done
using the Prism 3.0 software (Graph Pad, San Diego, son test. To compare clinical characteristics between re-
sponders and nonresponders, the Mann-Whitney test orCA, USA). Statistical comparisons between controls, re-
sponders, and nonresponders were done by analysis of the chi-square test was used. Differences were consid-
ered significant at P , 0.05. The relationship betweenvariance (ANOVA) and Bonferroni’s multiple compari-
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Fig. 3. Expression of B7-2 on CD141 monocytes of patients with
chronic renal failure (CRF) not yet treated by hemodialysis. There was
Fig. 2. Relationship between the expression density (MFI) of B7-2 no difference to healthy controls.
(secondary signal for T-cell activation) and HLA-DR (first signal) on
freshly isolated monocytes. *P , 0.05; **P , 0.01.
expression of B7-2 is not a side effect of globally impaired
expression of differentiation markers on monocytes ofB7-2 expression and proliferation results was estimated
dialysis patients or of physical influences of dialysis treat-by linear regression analysis.
ment, which would also affect surface molecules other
than B7-2. This is further supported by normal expres-
RESULTS sion levels of the differentiation marker CD14 in dialy-
sis patients (Fig. 1C). During T-cell activation, theSurface antigens on freshly isolated CD14-positive
HLA-DR molecule represents the first signal, while B7cells of hemodialysis patients
molecules provide an important costimulatory signal.The expression of molecules of the B7-family was de-
Since T-cell activation depends on the relationship be-termined on PBMCs by two-color flow cytometry with
tween both signals, the ratio between the expression ofelectronic gating on CD14-positive monocytes. Great
HLA-DR and B7-2 represents an important parametercare was taken to avoid cell activation during the prepa-
to determine the quality and quantity of T-cell response.ration procedure. Hemodialysis patients were stratified
The level of costimulation (B7-2) in relationship to theaccording to their response to a standardized vaccination
first signal (HLA-DR) was significantly lower in dialysisagainst hepatitis B. Results were compared between 20
patients with low immune competence (hepatitis B non-hemodialysis patients: 12 were responders and 8 nonre-
responders; Fig. 2).sponders to the vaccination, 10 CRF patients were not
The expression of B7-2 was also tested on monocyteson dialysis (B7-2 analysis only), and 12 healthy controls.
of CRF patients. In contrast to hemodialysis patients,There was only background expression of B7-1 on
they did not differ from healthy controls (Fig. 3).monocytes of freshly isolated unstimulated PBMCs in
either group. In all specimens, less than 10% of the CD14
Surface expression of stimulatory antigens afterpositive cells were positive for B7-1, with a mean of 4.1 6
culture and stimulation0.9% positives. The percentage of B7-1–positive cells
In addition to the measurements in freshly isolatedwas equal in patients and healthy controls.
monocytes, which reflect the situation at the initiationExpression of B7-2 on monocytes of freshly isolated
of an immune response, the expression of antigens wasPBMCs was significantly lower in cells from dialysis pa-
also tested after culture and stimulation of monocytestients compared with healthy controls (Fig. 1A). Strat-
in order to reflect the changes during the later course ofification of the patients with regard to their clinical im-
immune activation. After 20 hours of culture withoutmune response indicated a relationship between immune
further stimuli in vitro, the expression of B7-2 still tendedfunction and expression density of B7-2. Patients who
to be lower on monocytes of dialysis patients; however,did not respond to the hepatitis B vaccine had a lower
this finding was no longer statistically significant (Table 2).expression of B7-2 on monocytes than patients who re-
Culture with either 200 U/mL IFN-g or 300 mg/mLsponded with the production of antibodies as well as
cAMP led to a strong induction of B7-2 in all individuals,healthy controls.
which is in line with earlier data from the literatureThe expression of HLA-DR molecules on CD14-posi-
[14, 15]. Although expression density also increased intive cells did not differ between the patient groups or
between patients and controls (Fig. 1B). Therefore, low the dialysis patients, the induced expression was lower
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Table 2. Expression of B7-2 on monocytes of healthy controls and
hemodialysis patients stratified according to their response to
hepatitis B vaccination after culture of PBMC for 20 hours
with IFN-g (200 U/mL) or cAMP (300 mg/mL)
Controls Responder P Nonresponder P
Unstimulated 28.9 6 10.4 25.9 6 11.1 NS 22.5 6 3.5 NS
IFN-g 46.9 6 14.7 35.5 6 16.0 NS 30.1 6 6.7 ,0.05
cAMP 79.3 6 28.6 53.1 6 23.6 ,0.05 55.9 6 18.9 ,0.05
Data are means 6 SD of mean fluorescence intensity. P values compare patient
groups with respective healthy controls. P , 0.05 was considered significant; NS
is not significant.
Table 3. Expression of B7-1 and its relationship to B7-2 on
monocytes of healthy controls and hemodialysis patients stratified
according to their response to hepatitis B vaccination after
culture of PBMC for 20 hours with IFN-g (200 U/mL)
Controls Responder Nonresponder
B7-1 (MFI) 14.766.8 13.265.6 13.363.5
B7-2/B7-1 3.561.4 2.760.6 2.460.7
Data are means 6 SD of mean fluorescence intensity. There were no statisti-
cally significant differences.
in the nonresponder group (IFN-g and cAMP) and the
responder group (only cAMP; Table 2). It can be as-
sumed that during an immune response, the expression
level of B7-2 remains lower in dialysis patients compared
with healthy persons. Up-regulation of B7-2 by IFN-g
was normal in CRF patients (MFI, CRF 348 6 128; Fig. 4. (A) Proliferation of PBMCs as detected by the incorporation
of 3H-thymidine after culture of cells with 250 ng/mL PHA. *P , 0.05;controls 395 6 119, P 5 0.40).
**P , 0.01. (B) Correlation between the expression of B7-2 on native
While there is only marginal expression of B7-1 on monocytes and the proliferation during culture with PHA. Symbols are
(s) healthy controls; (m) responders; (d) nonresponders. There wasresting monocytes, this molecule is also up-regulated by
a linear relationship for dialysis patients (straight line, r 2 5 0.45, P ,activation via IFN-g [16]. In contrast to B7-2, there was 0.005) but not for healthy controls (dotted line, r 2 5 0.07, P 5 NS).
no difference in the activation-induced expression of
B7-1 between patients and controls (Table 3). Conse-
quently, the ratio between B7-2 and B7-1 after culture
The proliferation was related to the expression of B7-2with IFN-g tended to be reduced in nonresponder dial-
on native monocytes (Fig. 4B) with the lowest prolifera-ysis patients. In line with our earlier findings [17], B7-1
tion in cells from patients with the lowest expression ofcould not be up-regulated by cAMP (data not shown).
B7-2. This correlation between both parameters was statis-
tically significant in only the dialysis patient groups, whileRelationship between the expression of B7-2 on native
no such relationship could be found between B7-2 andmonocytes and in vitro T-cell activation
in vitro proliferation of lymphocytes in healthy controls.
Expression of costimulatory molecules such as B7-1
and B7-2 is highly relevant for the activation of T lym-
phocytes. In vitro T-cell activation studies were done to DISCUSSION
test the biological relevance of the reduced expression At least two distinct signals from APCs are required
of B7-2 in hemodialysis patients. Isolated PBMCs com- for the effector activation of CD41 T cells [9]. The
prising monocytes and lymphocytes were activated by primary signal is transmitted from the MHC class II
PHA at a concentration rendering T-cell activation de- molecule and the antigenic peptide to the T-cell receptor.
pendent on costimulatory function of the accessory cells. The secondary signal can be provided by costimulatory
The uptake of 3H-labeled thymidine as a measure of lym- molecules such as those of the B7 family. While the
phocyte proliferative response was lower in cultures from primary signal determines antigen specificity of a cellular
reaction, the secondary signal determines the mode ofdialysis patients than from healthy controls (Fig. 4A).
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reaction. In the absence of B7 signals, the T cell becomes the up-regulation of B7-1, which has a slower but sus-
anergic to the particular antigen [18, 19]. tained binding characteristic to the ligands on the CD41
In patients with CRF, a diminished T-cell activation T cell [25], leads to an enhancement of the costimulatory
leads to a high susceptibility for infectious complications. signal. Within the same time frame, the T cell expresses
Earlier work could characterize several typical features CTLA-4, the B7 ligand with the much higher binding
of the T-cell activation defect in these patients. First, the avidity than CD28 [14]. Engagement of CTLA-4 leads
low levels of T cell proliferation that parallel clinical to a down-regulation of T cell activation and thus seems
signs such as nonresponse to hepatitis B vaccination are to be a physiologic mechanism to limit effector cell activ-
accompanied by a reduced production of the autocrine ity [26]. A reduced expression of B7 molecules during
growth factor IL-2 by these cells [6, 8]. As a compensa- the early stage of immune recognition could easily re-
tory mechanism, the cell surface expression of IL-2 re- duce the function of the surface microdomains that are
ceptors on the T cell is enhanced [7, 20]. Exogenous required for optimal T-cell activation and thus reduce
supplementation of IL-2 is able to recover lymphocyte overall activation of T effector cells.
activation [21]. Second, the low activation of T cells in Engagement of CD28 on T cells in the presence of a
vitro is found only in the presence of autologous APCs. primary signal through the T cell receptor enhances the
The proliferative response of these T cells is normal in production of IL-2, which in an autocrine and paracrine
the presence of monocytes from healthy persons, indicat- way, supports T cell activation and clonal expansion [11].
ing that the defect is localized on the APCs rather than It can be assumed that the low expression density of
the T lymphocytes themselves [6, 8]. Finally, in vitro B7-2 during T cell activation is causally involved in the
T-cell activation in the presence of autologous APCs can deficient production of IL-2 by T cells from dialysis pa-
be normalized by the supplementation of B7-like signals, tients. Although additional variations in the expression
either by antibodies to the B7 ligand CD28 or by the of CD28 or CTLA-4 cannot be excluded, a direct associa-
addition of otherwise inert cells transfected with human tion of the defect with B7-2 is also supported by earlier
B7 molecules [6]. data that showed reconstitution of IL-2 production by
In the present study, we show that monocytes from the addition of anti-CD28 antibodies to the culture [6].
chronic hemodialysis patients have low levels of B7-2 As a consequence of impaired expression of B7-2, the
molecules on their surface. This defect was not found in immune system is unable to mount a full-blown reaction
CRF patients, possibly indicating an important role ei- toward the foreign antigen, the virus, bacterium, or vac-
ther of the severity of uremia or the dialysis procedure cine. Since the production of specific antibodies to sev-
itself. With regard to this observation, it has to be as- eral antigens is dependent on T cell help for the B lym-
sumed that the dialysis dose in the patients studied here
phocytes, this defect may also lead to reduced production
was quite low and did not meet current DOQI recom-
of antibodies. The functional relevance of the data onmendations. Preliminary findings suggest that increasing
B7-2 is strongly supported by the finding that the levelsthe dialysis dose might improve immune function and
of B7-2 on freshly isolated monocytes are directly relatedexpression of B7-2 (unpublished results).
to the clinical response of patients upon a vaccinationB7-2 is the constitutively expressed isoform of the B7-
against hepatitis B.molecules on monocytes [22]. Therefore, B7-2 molecules
Costimulatory requirements of naive CD41 T cellsare present at the very start of the immune recognition.
and primed memory cells are different [27]. SignalingThe functionally similar molecule B7-1 is up-regulated
through the B7-CD28 interaction is particularly relevantduring the immune response and seems to provide a
for the activation of naive helper cells. In contrast,confirmatory second signal. However, it takes between
primed CD41 cells can also be activated for proliferation24 and 48 hours until the full expression of B7-1 is
without the B7 signal if the original priming took placereached [23]. Despite the fact that B7-1 and B7-2 have
in a normal signaling environment. Thus, one speculationonly a 25% sequence homology, they bind to the same
could be that nonresponsiveness toward pathogens orligands on T cells. Several studies indicated that a specific
vaccines in patients with CRF mainly occurs if the patienttemporal pattern of expression and interaction between
was immunologically naive for the particular pathogen.the B7 molecules and their counterparts on T cells leads
On the other hand, the individual patient might react toto a tightly controlled activation of CD41 T cells [10].
antigens for which he or she has memory T cells avail-At the very beginning of an interaction between APCs
able. This provides a possible explanation for the obser-and CD41 T cells, the secondary signal is transmitted
vation of a significant but not complete concordancebetween B7-2 and CD28. The interaction is facilitated
between the responses after vaccination of dialysis pa-by the formation of so called “rafts,” which are microdo-
tients against hepatitis B and tetanus. In an earlier study,mains on the cell surface formed of several kinases that
we found that most (84%) of the patients who had re-through B7-CD28 interaction associate with the T-cell
receptor and mediate signal transduction [24]. Later on, sponded to the hepatitis B vaccination also responded to
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